stockrowMadrigal Pharmaceuticals, Inc. (MDGL) vs Spyre Therapeutics, Inc. (SYRE)
- Madrigal Pharmaceuticals, Inc. MDGL 394.08 −1.50%
- Spyre Therapeutics, Inc. SYRE 103.23 +6.87%
Madrigal Pharmaceuticals, Inc. and Spyre Therapeutics, Inc. are both Biotechnology companies. Madrigal Pharmaceuticals, Inc. and Spyre Therapeutics, Inc. are of similar size ($9.3B and $9.2B). Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 92.8% against −81.8%. Spyre Therapeutics, Inc. has the higher net margin (0.00% vs −10.9%) and the higher return on invested capital (0.00% vs −1,480.3%). Across the 17 metrics below, Spyre Therapeutics, Inc. leads on 9 and Madrigal Pharmaceuticals, Inc. on 8.
Valuation
Profitability
| Metric | MDGL | SYRE | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.96% | 100.00% | 65.16% |
| Operating margin | (10.69%) | 0.00% | 0.00% |
| Net margin | (10.89%) | 0.00% | 0.00% |
| Free cash flow margin | (11.81%) | 0.00% | 0.00% |
| Return on equity | (24.82%) | (41.15%) | (50.12%) |
| Return on assets | (11.12%) | (30.89%) | (45.60%) |
| Return on invested capital | (1,480.32%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack